ANDA 91232, held by Xiromed. Ethinyl Estradiol; Norgestimate.
As of Nov 16, 2026, ANDA 91232 (Tri-Lo-Estarylla), held by Xiromed, was first approved by FDA on Jun 29, 2015, with 3 approved supplements and 0 published complete response letters.
Tri-Lo-Estarylla (norgestimate and ethinyl estradiol tablets) is an estrogen/progestin COC, indicated for use by women to prevent pregnancy. 1.1 Oral Contraception Tri-Lo-Estarylla (norgestimate and ethinyl estradiol tablets) are indicated for use by females of reproductive potential to prevent pregnancy.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 29, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Tri-Lo-Estarylla0.025MG,0.025MG,0.025MG;0.18MG,0.215MG,0.25MG · tablet;oral-28 | Ethinyl Estradiol; Norgestimate | Rx |
| Apr 29, 2022 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 15, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 15, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Jun 29, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters